You can buy or sell HRTX and other stocks, options, ETFs, and crypto commission-free!
Heron Therapeutics, Inc. Common Stock, also called Heron Therapeutics, is a biotechnology company, which develops pharmaceutical products for patients suffering from cancer. Read More The company develops products by using its proprietary Biochronomer polymer based drug delivery technology. Its products include SUSTOL, Pipeline, Cinvanti and HTX-011. The company has additional clinical and preclinical-stage programs in the area of pain management, all of which utilize its bio erodible, injectable and implantable delivery systems. Heron Therapeutics was founded in February 1983 and is headquartered in Redwood City, CA.
San Diego, California
52 Week High
52 Week Low
Stock Price, News, & Analysis for Heron Therapeutics
Heron Therapeutics, Inc., a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron) extended-release injection for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associat...
Yahoo FinanceFeb 22
Heron Therapeutics: 4Q Earnings Snapshot
SAN DIEGO (AP) _ Heron Therapeutics Inc. (HRTX) on Friday reported a loss of $49.6 million in its fourth quarter. On a per-share basis, the San Diego-based company said it had a loss of 63 cents. The results did not meet Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 46 cents per share. The pharmaceutical company posted revenue of $28.8 million in the period, surpassing Street forecasts. Four analysts surveyed by Zacks expected $28.1...
Expected May 9, Pre-Market